Elizabeth Kelly

aVP, Head of Late Stage Immunology

United States

Research Interests

Explore related searches

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (10)

Collaborators (5)

Peter Richmond

University of Western Australia

Simon Royal

UNITED KINGDOM

Ruth Payne

University of Sheffield

UNITED KINGDOM

Christopher Green

University of Birmingham

UNITED KINGDOM

Robert Jan Lebbink

Associate professor

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Elizabeth Kelly

Research Interests

Explore related searches

Contact this professor

Articles (10)

Collaborators (5)

Peter Richmond

Simon Royal

Ruth Payne

Christopher Green

Robert Jan Lebbink

Make your next move.

Elizabeth Kelly

Research Interests

Explore related searches

Contact this professor

Articles (10)

Molecular and phenotypic characteristics of respiratory syncytial virus isolates recovered from medically vulnerable children: An exploratory analysis of a phase 2/3 randomized, double-blind, palivizumab-controlled trial of nirsevimab (MEDLEY)

Long-Term Safety and Immunogenicity of AZD1222 (ChAdOx1 nCoV-19): 2-Year Follow-Up from a Phase 3 Study

Immunogenicity and safety of beta variant COVID-19 vaccine AZD2816 and AZD1222 (ChAdOx1 nCoV-19) as primary-series vaccination for previously unvaccinated adults in Brazil, South Africa, Poland, and the UK: a randomised, partly double-blinded, phase 2/3 non-inferiority immunobridging study.

Seasonal human coronavirus humoral responses in AZD1222 (ChaAdOx1 nCoV-19) COVID-19 vaccinated adults reveal limited cross-immunity.

The genomic evolutionary dynamics and global circulation patterns of respiratory syncytial virus

Seropersistence of SII-ChAdOx1 nCoV-19 (COVID-19 vaccine): 6-month follow-up of a randomized, controlled, observer-blind, phase 2/3 immuno-bridging study in Indian adults.

Mediation of antitumor activity by AZD4820 oncolytic vaccinia virus encoding IL-12.

Immunogenicity and safety of AZD2816, a beta (B.1.351) variant COVID-19 vaccine, and AZD1222 (ChAdOx1 nCoV-19) as third-dose boosters for previously vaccinated adults: a multicentre, randomised, partly double-blinded, phase 2/3 non-inferiority immunobridging study in the UK and Poland

Analysis of SARS-CoV-2 Emergent Variants Following AZD7442 (Tixagevimab/Cilgavimab) for Early Outpatient Treatment of COVID-19 (TACKLE Trial).

Fc-mediated functions of nirsevimab complement direct respiratory syncytial virus neutralization but are not required for optimal prophylactic protection

Collaborators (5)

Peter Richmond

Simon Royal

Ruth Payne

Christopher Green

Robert Jan Lebbink

Make your next move.